Role of thrombin-activatable fibrinolysis inhibitor in lipopolysaccharide-induced acute lung injury Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
Effect of a thrombin inhibitor on murine bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 83s Year: 2003
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 461s Year: 2005
Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002
Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016
Thrombin activatable fibrinolytic inhibitor in sera from NSCLC patients Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005
Effect of neutrophil elastase inhibitor on airway inflammation and airway hyperresponsiveness in a murine model of asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
5-lipoxygenase inhibitor therapy in IPF Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
Metalloproteinase-9 and tissue inhibitor of metalloproteinase in baker‘s asthma Source: Eur Respir J 2005; 26: Suppl. 49, 603s Year: 2005
Decreased levels of secretory leucoprotease inhibitor in the pseudomonas -infected cystic fibrosis lung are due to neutrophil elastase degradation Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009
Role of thrombin and thrombin receptor in the activation of human bronchial epithelial cells during airway inflammation Source: Eur Respir J 2007; 30: Suppl. 51, 523s Year: 2007
Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018
Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema Source: Eur Respir J 2002; 19: 1050-1057 Year: 2002
Increased serum concentration of urinary trypsin inhibitor with asthma exacerbation Source: Eur Respir J 2003; 22: 739-742 Year: 2003
Assessment of in vivo 5-lipoxygenase (5-LO) activity in nonatopic and atopic subjects with or without asthma: effects of treatment with the 5-LO inhibitor zileuton Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS Source: Annual Congress 2012 - How to use technology to provide better critical care Year: 2012
Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010